SCHEMBL5410091

SCHEMBL5410091

CNc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1NC(=O)N(C)C

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ APEX1 P27695 1/20 0.53
▸ HDAC3 O15379 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ LRRK2 Q5S007 7/20 0.45
▸ STK17A Q9UEE5 2/20 0.44
▸ STK17B O94768 1/20 0.44
▸ JAK2 O60674 2/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ SYK P43405 2/20 0.41
▸ ALK Q9UM73 3/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ INSR P06213 1/20 0.40
▸ MAPK3 P27361 1/20 0.40
▸ ULK1 O75385 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5414041 0.88 STK17A (0.44) APEX1HDAC3HDAC1HDAC2HDAC6
SCHEMBL5422198 0.88 STK17A (0.42) APEX1HDAC3HDAC1HDAC2HDAC6
SCHEMBL5418520 0.88 LRRK2 (0.49) APEX1HDAC3HDAC1HDAC2HDAC6
SCHEMBL5415948 0.87 HDAC3 (0.49) HDAC3HDAC1HDAC2HDAC6LRRK2
SCHEMBL5415421 0.86 STK17A (0.48) HDAC3HDAC1HDAC2HDAC6LRRK2
SCHEMBL5408198 0.86 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC6LRRK2
SCHEMBL5414042 0.86 STK17A (0.43) APEX1HDAC3HDAC1HDAC2HDAC6
SCHEMBL5418427 0.85 HDAC3 (0.47) HDAC3HDAC1HDAC2HDAC6LRRK2
SCHEMBL5413822 0.84 CYP3A4 (0.53) HDAC3HDAC1HDAC2HDAC6LRRK2
SCHEMBL5416137 0.84 HDAC3 (0.46) HDAC3HDAC1HDAC2HDAC6LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 APEX1 1037/4885HDAC3 4754/4885HDAC1 3995/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 APEX1 1581/4885HDAC3 4861/4885HDAC1 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback